Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHAUDRY AHMAD WAHEED CHEEMA

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1659375343
CMS profile
347739
Location
ROCK ISLAND, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,850.30

61 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,796.76 57
Education $53.54 4

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHAUDRY AHMAD WAHEED CHEEMA

NPI 1659375343 · CMS profile ID 347739

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ROCK ISLAND, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659375343?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHAUDRY AHMAD WAHEED CHEEMA, NPI 1659375343, CMS profile ID 347739. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659375343?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). CHAUDRY AHMAD WAHEED CHEEMA, NPI 1659375343, CMS profile ID 347739. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659375343?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
CHAUDRY AHMAD WAHEED CHEEMA, NPI 1659375343, CMS profile ID 347739, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1659375343?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

61 matching records · $1,850.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 61 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–61 of 61.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $21.0603/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078603936 CMS
ABBVIE INC. $23.1803/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103450608 CMS
Phathom Pharmaceuticals, Inc. $19.7103/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151048618 CMS
ABBVIE INC. $7.1403/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103450606 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.3202/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137508949 CMS
Phathom Pharmaceuticals, Inc. $103.6102/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151048616 CMS
ABBVIE INC. $22.3302/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103450604 CMS
ABBVIE INC. $11.1701/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103450602 CMS
ABBVIE INC. $21.8801/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103450600 CMS
Regeneron Healthcare Solutions, Inc. $16.5501/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114023028 CMS
Braintree Laboratories, Inc. $15.5201/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125513589 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,581.83 92
PY2020 $6,867.28 45
PY2021 $2,372.70 58
PY2022 $1,536.07 77
PY2023 $1,187.14 56
PY2024 $1,850.30 61
PY2025 $1,302.37 57

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2020 Principal investigator $10,739.53 31
PY2019 Recipient $678.42 1
PY2019 Principal investigator $17,786.92 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $1,385.13 12/31/2020 Non-covered Recipient Entity
GEN1 RESEARCH LLC
A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with moderately to Severely Active Croh No dispute reported 06/30/2026 721315607
Principal investigator 1 Allergan, Inc. $1,991.40 12/31/2020 Non-covered Recipient Entity
GEN1 RESEARCH LLC
A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 721315725
Principal investigator 1 Allergan, Inc. $169.00 08/13/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721289803
Principal investigator 1 Allergan, Inc. $700.00 08/11/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721289401
Principal investigator 1 Allergan, Inc. $86.00 07/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721286487
Principal investigator 1 Allergan, Inc. $86.00 07/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721286605
Principal investigator 1 Allergan, Inc. $86.00 07/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721286667
Principal investigator 1 Allergan, Inc. $86.00 07/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721286827
Principal investigator 1 Allergan, Inc. $86.00 07/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721285797
Principal investigator 1 Allergan, Inc. $86.00 07/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721283411
Principal investigator 1 Allergan, Inc. $225.00 04/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721273055
Principal investigator 1 Allergan, Inc. $86.00 03/26/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721267391
Principal investigator 1 Allergan, Inc. $86.00 03/26/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721267441
Principal investigator 1 Allergan, Inc. $86.00 03/17/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721264657
Principal investigator 1 Allergan, Inc. $86.00 03/17/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721264753
Principal investigator 1 Allergan, Inc. $218.00 03/17/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721264827
Principal investigator 1 Allergan, Inc. $955.00 03/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721262737
Principal investigator 1 Allergan, Inc. $86.00 02/25/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721259921
Principal investigator 1 Allergan, Inc. $115.00 01/30/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721254825
Principal investigator 1 Allergan, Inc. $700.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721251021
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721251491
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721251749
Principal investigator 1 Allergan, Inc. $945.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721251965
Principal investigator 1 Allergan, Inc. $315.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721253693
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721254069
Principal investigator 1 Allergan, Inc. $315.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721246045
Principal investigator 1 Allergan, Inc. $315.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721246239
Principal investigator 1 Allergan, Inc. $315.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721246413
Principal investigator 1 Allergan, Inc. $700.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721246461
Principal investigator 1 Allergan, Inc. $86.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721246491
Principal investigator 1 Allergan, Inc. $86.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721246863